The government is not equipped to go into the pharmaceutical business, and facilitating that is a slippery slope. It would also be enormously expensive. Reform of the Orphan Drug Act , which ended up creating windfalls for companies, is needed, and this problem could be included. The problem is that Congress isn't motivated to address these issues and actually come up with and pass fixes.